ABL Bio
| Market cap | ₩2.9T |
| PE ratio | – |
| Forward PE | – |
| PB ratio | 17.14 |
| EPS | −₩1,420 |
| Dividend (yield) | – |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 295,866 |
| Trading value | ₩15.6B |
| Day’s range | ₩51,100 – ₩54,100 |
| 52-week range | ₩47,350 – ₩257,500 |
| Foreign ownership KR | 14.95% |
| Foreign net buy (Oct 2) KR | −67,244 sh |
| Book value / share | ₩3,063 |
| Founded | 2016 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩51,400 | −67,244 | −600 | +68,146 | 14.95% |
| Oct 1 | ₩53,600 | +19,872 | +78,251 | −96,362 | 15.18% |
| Sep 30 | ₩48,500 | −912 | −25,123 | +26,207 | 15.25% |
| Sep 29 | ₩49,300 | +76,296 | −50,041 | −12,682 | 15.32% |
| Sep 28 | ₩50,200 | −11,302 | −18,815 | +28,853 | 15.16% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩65.5B | ₩33.4B | ₩79.3B | – |
| Operating income | −₩2.6B | −₩59.4B | −₩40.4B | – |
| Net income | −₩2.6B | −₩55.5B | −₩37.9B | – |
| Operating margin | −3.99% | −177.76% | −50.90% | – |
| Return on equity | −3.69% | −46.01% | −23.48% | – |
| Debt-to-equity | 116.18% | 38.67% | 79.29% | – |
| EPS | −₩55 | −₩1,094 | −₩693 | – |
| Dividend per share | – | – | – | – |
Peers
| Alteogen 196170 | ₩260,000 | +0.19% |
| Peptron 087010 | ₩130,600 | +0.85% |
| Hugel 145020 | ₩181,500 | +0.78% |
| D&D Pharmatech 347850 | ₩47,550 | +10.58% |
| Aimed Bio 0009K0 | ₩25,800 | +4.03% |
| Naturecell 007390 | ₩24,750 | 0.00% |
About
ABL Bio develops biologic drugs based on bispecific antibody technology. Using its Grabody bispecific platform, it researches antibody therapies including immune checkpoint modulators, new cancer targets, treatments for degenerative brain diseases with better blood-brain barrier (BBB) penetration, and ADCs. Its US unit NEOK Bio handles ADC clinical development. Founded in 2016, it listed on the KOSDAQ in 2018.
ABL Bio Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 298380. Industry: Pharmaceuticals.
ABL Bio in our notes
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 6, 2026; investor flows as of Oct 2, 2026. Delayed data, not investment advice.